Eftrenonacog Alfa

CHEMBL4594598 Phase 4 Aprovado Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This long-acting form of clotting factor IX is used to prevent and treat bleeding episodes in people with hemophilia B. It works by replacing the missing clotting factor needed for normal blood clotting.

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This long-acting form of clotting factor IX is used to prevent and treat bleeding episodes in people with hemophilia B. It works by replacing the missing clotting factor needed for normal blood clotting.

Yes, Eftrenonacog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594598. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.